20.2 Quality Control, Proficiency Testing, and Regulation
Key Takeaways
- FDA regulates blood as a biologic: 21 CFR 606 (cGMP), 600/610 (biologics general standards), and 630 (donor eligibility). Licensed establishments may ship in interstate commerce; unlicensed registered establishments generally may not.
- AABB Standards, 35th edition (effective 1 April 2026), are voluntary professional standards used for accreditation. They do not replace FDA or CLIA. CAP and The Joint Commission accredit many hospital transfusion services.
- Immunohematology is CLIA high-complexity testing under 42 CFR 493. Competency uses all six CLIA elements, at 6 months and annually in the first year for new staff, then at least annually.
- Biological product deviations are reported under 21 CFR 606.171 when a manufacturing deviation or unexpected event involved a distributed product and may have affected safety, purity, or potency — as soon as possible, not more than 45 calendar days from discovery.
- Proficiency testing is graded external challenge, not daily reagent QC. Unsuccessful PT requires investigation and corrective action before the next event is simply ‘tried again.’
20.2 Quality Control, Proficiency Testing, and Regulation
Quick Answer: FDA owns blood as a biologic (21 CFR 606 cGMP, 600/610 biologics standards, 630 donor eligibility). CLIA (42 CFR 493) owns the testing. Immunohematology is high complexity. AABB Standards, 35th edition (effective 1 April 2026) are voluntary and used for accreditation — they are not a federal statute. CAP and The Joint Commission accredit hospital labs. OSHA owns the workplace. Report a biological product deviation when distributed product may have lost safety, purity, or potency, within 45 calendar days. Do not invent inspection scores.
The June 9, 2026 outline splits VI.A between troubleshooting (20.1) and this QC/regulatory layer. Daily reagent and instrument QC lives in Chapter 16.2; do not re-memorize vial colors here. This section is who has legal authority, who accredits, how competency and PT work, and when FDA must be told. Budgets, staffing models, and IQCP administration are SBB-weighted, not BB.
FDA: cGMP, biologics, and donor rules
Blood and blood components are biologics. The operational CFR map for BB is:
- 21 CFR 600 — general biologics administrative rules (licensing framework, BPD companion at 600.14 for some products).
- 21 CFR 606 — current good manufacturing practice for blood and blood components: personnel, facilities, equipment, SOPs, records, labeling control, storage, and 606.171 BPD reporting.
- 21 CFR 610 — general biological-products standards: required tests, dating periods, sterility concepts, restrictions on shipment or use.
- 21 CFR 630 — donor eligibility (Chapter 2.1).
- 21 CFR 640 — additional manufacturing standards for Whole Blood, Red Blood Cells, Platelets, Plasma, Cryoprecipitated AHF (Chapter 3.1).
cGMP means the process is under control before a unit is pretty. Written procedures, validated equipment, controlled labels, quarantine until release, and records that reconstruct every unit are the exam translation. A hospital that only receives already-labeled units and performs compatibility testing is primarily a CLIA laboratory. The moment that hospital manufactures — collects autologous units, irradiates, washes, freezes/deglycerolizes, pools, or aliases a product — FDA registration questions start.
Licensed versus unlicensed registered establishments
Two FDA statuses are not interchangeable.
Registration (21 CFR 607) is the establishment list: you manufacture blood products, so FDA knows you exist and you list those products. Licensure (PHS Act section 351 biologics license) is permission to introduce those products into interstate commerce. A community blood center that ships red cells across a state line is a licensed blood establishment. A hospital transfusion service that collects a few autologous units for in-house use may be registered but unlicensed. Unlicensed products generally stay in-state. You cannot fix an inventory shortage by quietly shipping unlicensed autologous leftovers to a sister hospital in another state.
Both licensed manufacturers and unlicensed registered blood establishments file blood BPDs under 21 CFR 606.171. Licensure is not a free pass and lack of a license is not an excuse to skip the report.
A hospital that only type-and-crosses licensed products received from a supplier typically has no FDA blood-establishment license and may have no FDA registration if it does not manufacture. It still has a CLIA certificate, and it still answers to AABB/CAP/TJC if it holds those accreditations. The exam trap is treating every hospital blood bank as if it were an FDA-licensed manufacturer — or treating FDA as optional because “we are CAP.”
AABB, CLIA, CAP, Joint Commission, OSHA
| Body | What it is | What BB must remember |
|---|---|---|
| FDA (21 CFR 600/606/610/630/640) | Federal law for biologics manufacturing | cGMP, donor eligibility, labeling, BPD, recall |
| CLIA (42 CFR 493) | Federal law for clinical testing | High-complexity immunohematology; SOP, QC, PT, competency, director duties |
| AABB Standards 35th ed. (1 April 2026) | Voluntary professional standards + accreditation | Many hospitals choose AABB; not a substitute for FDA or CLIA |
| CAP | Accreditation (CMS-deemed pathway) | Checklist inspection of the transfusion service |
| The Joint Commission | Hospital accreditation | National Patient Safety Goals, identification, transfusion documentation |
| OSHA | Workplace safety law | Bloodborne pathogens and chemical hygiene (Chapter 20.3) |
AABB Standards for Blood Banks and Transfusion Services, 35th edition, effective 1 April 2026, is the current AABB book this guide uses. It is voluntary. A transfusion service can be legally open with CLIA and without AABB. Many academic and large community hospitals still seek AABB accreditation because insurers, transplant programs, and medical staff expect it. On a stem, AABB language (“two independent identifiers,” 3-day specimen after transfusion/pregnancy, component storage ranges) is still the operational answer — just do not call AABB a federal agency.
CAP and The Joint Commission inspect the hospital laboratory and the bedside transfusion process. They do not issue biologics licenses. OSHA does not grade your antibody screen; it grades whether you protect the worker.
Do not invent unpublished inspection scores. FDA, CAP, AABB, and Joint Commission do not publish a national “percent of blood banks that failed 2026” number for you to memorize. If a stem offers a fake score, ignore it and answer the regulation.
Proficiency testing and the six CLIA competency elements
Proficiency testing (PT) is an external, graded challenge (CMS-approved provider) for regulated immunohematology events: ABO/Rh, antibody detection, antibody identification, and compatibility testing as your menu requires. Test PT samples like patient samples, within the event window, by staff who actually do the work. Do not send PT to a reference lab unless that is how patient samples travel. Do not discuss results with another laboratory before the due date. Unsuccessful PT (unsatisfactory event or unsuccessful performance) triggers investigation, corrective action, and sometimes cease-testing implications if the unsuccessful run is not fixed. PT is not the same as daily anti-A QC.
Competency is about the person, not the vial. CLIA requires all six elements for high-complexity testing, including immunohematology:
- Direct observation of routine patient test performance (specimen handling through testing).
- Monitoring the recording and reporting of results.
- Review of intermediate worksheets, QC records, PT results, and preventive-maintenance records.
- Direct observation of instrument maintenance and function checks.
- Assessment of test performance with previously analyzed specimens, internal blind samples, or external PT.
- Assessment of problem-solving skills (discrepancy, downtime, QC failure, antibody puzzle).
New employees who test patients need competency at 6 months and again by 12 months in the first year, then at least annually. A method or instrument change restarts competency for that test. A signed “I read the SOP” sheet is not six elements. Problem-solving is a required element — a blood bank that never asks a tech to work an ABO discrepancy for competency is incomplete.
Biological product deviation reporting
21 CFR 606.171 is the blood-specific BPD rule. Report when all of the following are true:
- A deviation from cGMP, applicable standards, or established specifications occurred, or an unexpected event occurred in manufacturing.
- The firm had control of the product when it happened.
- The product was distributed.
- The event may have affected safety, purity, or potency.
Report to FDA CBER as soon as possible, not more than 45 calendar days from the date you (or your agent) discovered information reasonably suggesting a reportable event. Both licensed and unlicensed registered blood establishments use this rule.
Distributed means it left your controlled inventory — issued to a patient-care area, shipped to a consignee, or otherwise released. A unit caught in quarantine inside your own refrigerator is an occurrence, not a BPD. An ABO-incompatible unit that reached the OR is reportable even if the nurse never spiked it, because it was distributed and SPP may have been affected.
Examples that commonly meet the bar: unit issued to the wrong patient, donor-testing not completed before distribution (outside the narrow 610.40(g) emergency path), incorrect expiration applied and the unit shipped, irradiation indicated but not performed on a unit issued to an at-risk patient, bacterial-detection protocol not completed on a platelet that was issued.
Examples that are usually not BPDs by themselves: a mislabeled tube discarded before testing, a reagent QC failure caught before any result was reported, a planned deviation that was approved and did not put distributed product at risk.
BPD reporting does not replace the occurrence file, the recall, or the patient-notification duty. It is the FDA manufacturing report. Late reporting is itself a cGMP problem. Do not wait 45 days on purpose — 45 is the ceiling, not the target.
A registered but unlicensed hospital blood bank ships two autologous red-cell units to an affiliate hospital across a state line to cover a holiday shortage. Which statement is correct?
A newly hired BB scientist has completed SOP sign-off and one successful external PT event. Which additional CLIA competency requirement is still missing for high-complexity immunohematology?
An irradiated red-cell unit intended for a neonate is issued to the NICU. After issue, staff discover the irradiation indicator is unchanged and the irradiator log has no entry for that DIN. The bag is unspiked and is retrieved 20 minutes later. What FDA reporting question must be asked?